Codexis (CDXS) Projected to Post Quarterly Earnings on Thursday

Codexis (NASDAQ:CDXS - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $10.38 million for the quarter. Codexis has set its FY 2025 guidance at EPS.

Codexis (NASDAQ:CDXS - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.09). The business had revenue of $21.46 million for the quarter, compared to the consensus estimate of $27.41 million. Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. On average, analysts expect Codexis to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Codexis Stock Performance

Shares of NASDAQ:CDXS remained flat at $2.33 during midday trading on Tuesday. The stock had a trading volume of 335,528 shares, compared to its average volume of 660,876. The company has a market capitalization of $193.01 million, a P/E ratio of -2.68 and a beta of 2.35. The company has a current ratio of 3.21, a quick ratio of 3.15 and a debt-to-equity ratio of 0.39. Codexis has a 1 year low of $1.90 and a 1 year high of $6.08. The stock's 50 day moving average price is $2.65 and its 200 day moving average price is $3.81.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.